Condition: CLL / SLL · CLL (Chronic Lymphocytic Leukemia) · SLL (Small Lymphocytic Lymphoma) · Sponsor: Lomond Therapeutics Holdings, Inc.
This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grad lymphomas.
This description comes directly from the study's public registry record.
Ekaterina Dokukina, PhD MD · +38269728309 · kdokukina@eileanther.com
Always discuss trial participation with your own doctor first.
| Norton Cancer Institute, St. Matthews Campus | Louisville, Kentucky, United States | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| University of Cincinnati | Cincinnati, Ohio, United States | Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06708897